<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Haematol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2141</journal-id><journal-id journal-id-type="publisher-id">BJH</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26085061</article-id><article-id pub-id-type="pmc">4744770</article-id><article-id pub-id-type="doi">10.1111/bjh.13563</article-id><article-id pub-id-type="publisher-id">BJH13563</article-id><article-categories><subj-group subj-group-type="overline"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Haematological Malignancy</subject></subj-group></article-categories><title-group><article-title>
<italic>CSNK1A1</italic> mutations and gene expression analysis in myelodysplastic syndromes with del(5q)</article-title><alt-title alt-title-type="left-running-head">Short Report</alt-title></title-group><contrib-group><contrib id="bjh13563-cr-0001" contrib-type="author"><name><surname>Bello</surname><given-names>Erica</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13563-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-note" rid="bjh13563-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="bjh13563-cr-0002" contrib-type="author"><name><surname>Pellagatti</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13563-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-note" rid="bjh13563-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="bjh13563-cr-0003" contrib-type="author"><name><surname>Shaw</surname><given-names>Jacqueline</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13563-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bjh13563-cr-0004" contrib-type="author"><name><surname>Mecucci</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bjh13563-cr-0005" contrib-type="author"><name><surname>Ku&#x00161;ec</surname><given-names>Rajko</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="bjh13563-cr-0006" contrib-type="author"><name><surname>Killick</surname><given-names>Sally</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="bjh13563-cr-0007" contrib-type="author"><name><surname>Giagounidis</surname><given-names>Aristoteles</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="bjh13563-cr-0008" contrib-type="author"><name><surname>Raynaud</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="bjh13563-cr-0009" contrib-type="author"><name><surname>Calasanz</surname><given-names>Mar&#x000ed;a J.</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="bjh13563-cr-0010" contrib-type="author"><name><surname>Fenaux</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="bjh13563-cr-0011" contrib-type="author" corresp="yes"><name><surname>Boultwood</surname><given-names>Jacqueline</given-names></name><xref ref-type="aff" rid="bjh13563-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bjh13563-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="bjh13563-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">LLR Molecular Haematology Unit</named-content><named-content content-type="organisation-division">Nuffield Division of Clinical Laboratory Sciences</named-content><named-content content-type="organisation-division">Radcliffe Department of Medicine</named-content><institution>University of Oxford</institution><named-content content-type="city">Oxford</named-content><country country="GB">UK</country></aff><aff id="bjh13563-aff-0002"><label><sup>2</sup></label><institution>NIHR Biomedical Research Centre</institution><named-content content-type="city">Oxford</named-content><country country="GB">UK</country></aff><aff id="bjh13563-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Haematology and Bone Marrow Transplantation Unit</named-content><institution>University of Perugia</institution><named-content content-type="city">Perugia</named-content><country country="IT">Italy</country></aff><aff id="bjh13563-aff-0004"><label><sup>4</sup></label><institution>Dubrava University Hospital and Zagreb School of Medicine</institution><institution>University of Zagreb</institution><named-content content-type="city">Zagreb</named-content><country country="HR">Croatia</country></aff><aff id="bjh13563-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Haematology</named-content><institution>Royal Bournemouth Hospital</institution><named-content content-type="city">Bournemouth</named-content><country country="GB">UK</country></aff><aff id="bjh13563-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Haematology, Oncology, and Palliative Care</named-content><institution>Marienhospital D&#x000fc;sseldorf</institution><named-content content-type="city">D&#x000fc;sseldorf</named-content><country country="DE">Germany</country></aff><aff id="bjh13563-aff-0007"><label><sup>7</sup></label><institution>Centre Hospitalier Universitaire Nice</institution><named-content content-type="city">Nice</named-content><country country="FR">France</country></aff><aff id="bjh13563-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Department of Genetics</named-content><institution>University of Navarra</institution><named-content content-type="city">Pamplona</named-content><country country="ES">Spain</country></aff><aff id="bjh13563-aff-0009"><label><sup>9</sup></label><institution>Service d'h&#x000e9;matologie seniors</institution><institution>H&#x000f4;pital St Louis</institution><named-content content-type="city">Paris</named-content><country country="FR">France</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence: Professor Jacqueline Boultwood, LLR Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.<break/>
E&#x02010;mail: <email>jacqueline.boultwood@ndcls.ox.ac.uk</email><break/></corresp><fn fn-type="equal" id="bjh13563-note-0001"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2015</year></pub-date><volume>171</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/bjh.2015.171.issue-2</issue-id><fpage>210</fpage><lpage>214</lpage><history><date date-type="received"><day>27</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>British Journal of Haematology</italic> published by John Wiley &#x00026; Sons Ltd</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:BJH-171-210.pdf"/><abstract id="bjh13563-abs-0001"><title>Summary</title><p>Mutations of <italic>CSNK1A1</italic>, a gene mapping to the commonly deleted region of the 5q&#x02010; syndrome, have been recently described in patients with del(5q) myelodysplastic syndromes (<styled-content style="fixed-case">MDS</styled-content>). Haploinsufficiency of <italic>Csnk1a1</italic> in mice has been shown to result in &#x003b2;&#x02010;catenin activation and expansion of haematopoietic stem cells (<styled-content style="fixed-case">HSC</styled-content>). We have screened a large cohort of 104 del(5q) <styled-content style="fixed-case">MDS</styled-content> patients and have identified mutations of <italic>CSNK1A1</italic> in five cases (approximately 5%). We have shown up&#x02010;regulation of &#x003b2;&#x02010;catenin target genes in the HSC of patients with del(5q) MDS. Our data further support a central role of CSNK1A1 in the pathogenesis of MDS with del(5q).</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bjh13563-kwd-0001">CSNK1A1</kwd><kwd id="bjh13563-kwd-0002">mutation</kwd><kwd id="bjh13563-kwd-0003">haploinsufficiency</kwd><kwd id="bjh13563-kwd-0004">5q&#x02010; syndrome</kwd><kwd id="bjh13563-kwd-0005">del(5q)</kwd></kwd-group><funding-group><award-group><funding-source>Leukaemia &#x00026; Lymphoma Research</funding-source></award-group></funding-group><counts><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bjh13563</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.6 mode:remove_FC converted:03.02.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell (HSC) malignancies characterized by ineffective haematopoiesis and peripheral blood cytopenias (Heaney &#x00026; Golde, <xref rid="bjh13563-bib-0010" ref-type="ref">1999</xref>). MDS patients typically have a hypercellular bone marrow. Approximately 40% of MDS cases progress to acute myeloid leukaemia (Heaney &#x00026; Golde, <xref rid="bjh13563-bib-0010" ref-type="ref">1999</xref>).</p><p>Deletion of the long arm of chromosome 5 [del(5q)] occurs in approximately 10&#x02013;20% of patients with <italic>de novo</italic> MDS (Giagounidis <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0008" ref-type="ref">2004</xref>; Boultwood <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0003" ref-type="ref">2010</xref>) and is the sole karyotypic abnormality in patients with the 5q&#x02010; syndrome, the most distinct of the MDS (Giagounidis <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0008" ref-type="ref">2004</xref>; Boultwood <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0003" ref-type="ref">2010</xref>). The commonly deleted region (CDR) of the 5q&#x02010; syndrome was identified and narrowed to a 1&#x000b7;5&#x000a0;Mb interval at 5q32 (Boultwood <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0001" ref-type="ref">2002</xref>). Several candidate genes map to the CDR, including <italic>CSNK1A1,</italic> which was found to be haploinsufficient (i.e. down&#x02010;regulated by approximately 50%) in the CD34<sup>+</sup> cells of 5q&#x02010; syndrome patients in a gene expression profiling (GEP) study (Boultwood <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0002" ref-type="ref">2007</xref>). In this setting the remaining copy of the gene does not compensate the loss of the other allele. Sanger sequencing&#x02010;based screening of all 40 genes within the CDR did not identify any mutations in a cohort of ten 5q&#x02010; syndrome patients. However, in a recent study (Schneider <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>), mutations of <italic>CSNK1A1</italic> were identified using whole&#x02010;exome sequencing in 2 of 19 del(5q) cases and a further <italic>CSNK1A1</italic> mutation was found in an additional cohort of 22 MDS cases with isolated del(5q) using next&#x02010;generation targeted sequencing, giving an overall frequency of approximately 7% in the MDS del(5q) cases analysed. This is the first report of mutations in a gene mapping to the CDR of the 5q&#x02010; syndrome, although these mutations are found in a small subset of del(5q) MDS patients (Schneider <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>). <italic>CSNK1A1</italic> encodes a serine/threonine kinase (CK1&#x003b1;), which has a regulatory role in the Wnt/&#x003b2;&#x02010;catenin and p53 signalling pathways (Elyada <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0005" ref-type="ref">2011</xref>). Schneider <italic>et&#x000a0;al</italic> (<xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>) showed that expression of mutant <italic>CSNK1A1</italic> resulted in &#x003b2;&#x02010;catenin activation and HSC cell cycle progression.</p><p>Heterozygous inactivation of <italic>Csnk1a1</italic> in mice also resulted in &#x003b2;&#x02010;catenin activation and expansion of HSCs, suggesting that <italic>CSNK1A1</italic> haploinsufficiency may be the mechanism underlying the initial clonal expansion in patients with the 5q&#x02010; syndrome (Schneider <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>).</p><p>In this study, firstly we have screened a large cohort of MDS cases with del(5q) for mutations in <italic>CSNK1A1</italic>. Secondly, we have investigated the impact of <italic>CSNK1A1</italic> haploinsufficiency and mutation on the expression of &#x003b2;&#x02010;catenin&#x02010;related genes in the CD34<sup>+</sup> cells from MDS patients with del(5q) using GEP.</p><sec id="bjh13563-sec-0002"><title>Materials and methods</title><sec id="bjh13563-sec-0003"><title>Patient samples</title><p>A total of 104 MDS cases with del(5q) were included in this study (Table&#x000a0;SI). Genomic DNA was isolated using phenol&#x02010;chloroform extraction from bone marrow samples or from peripheral blood neutrophils isolated using Histopaque (Sigma&#x02010;Aldrich, Gillingham, UK) and pelleted after hypotonic lysis of erythrocytes.</p></sec><sec id="bjh13563-sec-0004"><title>Sanger sequencing</title><p>Sanger sequencing was performed following polymerase chain reaction (PCR) amplification using the following primers: exon 3 of <italic>CSNK1A1</italic> forward primer 5&#x02032;&#x02010;TCCTTTTGTTTCGTTAGGTGGT&#x02010;3&#x02032; and reverse primer 5&#x02032;&#x02010;AAGGTTAAATAGTGATGCACAGGA&#x02010;3&#x02032;, exon 4 forward primer 5&#x02032;&#x02010;GCCAAAGGACACAGCAGGTA&#x02010;3&#x02032; and reverse primer 5&#x02032;&#x02010;CAGCAAATTCAACTTACTATGGC&#x02010;3&#x02032;.</p></sec><sec id="bjh13563-sec-0005"><title>GEP and data analysis</title><p>Gene expression profiling data on CD34<sup>+</sup> cells from a group of MDS patients with del(5q) and healthy controls were obtained from a dataset previously published by our group (Pellagatti <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0013" ref-type="ref">2010</xref>). The microarray platform used was the Affymetrix GeneChip Human Genome U133 Plus 2&#x000b7;0 (47&#x000a0;000 transcripts) (Affymetrix, Santa Clara, CA, USA). Analysis of gene set up&#x02010; or down&#x02010;regulation was performed using Gene Set Enrichment Analysis (GSEA) as previously described (Papaemmanuil <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0012" ref-type="ref">2011</xref>).</p></sec><sec id="bjh13563-sec-0006"><title>Real&#x02010;time quantitative PCR</title><p>Real&#x02010;time quantitative PCR reactions were run on a LightCycler 96 Real&#x02010;Time PCR System (Roche Diagnostics, Lewes, UK). Pre&#x02010;developed TaqMan Assays were used (Assays&#x02010;on&#x02010;Demand, Applied Biosystems, Foster City, CA, USA) and the expression level of the beta&#x02010;2&#x02010;microglobulin gene (<italic>B2M</italic>) was used to normalize for differences in input cDNA. Each sample was performed in triplicate and the expression ratios were calculated using the &#x00394;&#x00394;<italic>C</italic>
<sub>t</sub> method.</p></sec></sec><sec id="bjh13563-sec-0007"><title>Results and discussion</title><p>We have determined the frequency of <italic>CSNK1A1</italic> mutations in a large cohort of 104 cases of MDS with del(5q) using Sanger sequencing. Schneider <italic>et&#x000a0;al</italic> (<xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>) identified <italic>CSNK1A1</italic> mutations in del(5q) MDS in exon 3, and two previous studies (Graubert <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0009" ref-type="ref">2012</xref>; Woll <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0015" ref-type="ref">2014</xref>) reported <italic>CSNK1A1</italic> mutations in exon 4 of the gene. We therefore focused our investigation on the analysis of the sequences of exon 3 and 4 of <italic>CSNK1A1</italic>.</p><p>We identified missense mutations of <italic>CSNK1A1</italic> in five del(5q) MDS cases in our cohort (Table&#x000a0;<xref rid="bjh13563-tbl-0001" ref-type="table-wrap">1</xref>, Fig&#x000a0;<xref rid="bjh13563-fig-0001" ref-type="fig">1</xref>A). All five patients harbouring <italic>CSNK1A1</italic> mutations had refractory anaemia (two of which had the 5q&#x02010; syndrome). Two of the <italic>CSNK1A1</italic> mutations identified caused a previously reported amino acid change, E98K (Schneider <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>). An additional case harboured a different <italic>CSNK1A1</italic> mutation affecting amino acid 98 (E98G), previously described in other malignancies (Dulak <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0004" ref-type="ref">2013</xref>). Moreover, a previously reported <italic>CSNK1A1</italic> mutation at amino acid 140 (D140A) (Graubert <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0009" ref-type="ref">2012</xref>) was found in one case of MDS with isolated del(5q) in our study. We identified a novel <italic>CSNK1A1</italic> mutation at codon 134 (H134L) that has not been previously reported. The <italic>CSNK1A1</italic> mutations identified were analysed using the PolyPhen&#x02010;2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>) and SIFT (<ext-link ext-link-type="uri" xlink:href="http://sift.jcvi.org/">http://sift.jcvi.org/</ext-link>) online tools, in order to predict the effect of the mutations on protein function. All <italic>CSNK1A1</italic> mutations, including the newly identified H134L mutation, were reported as damaging by PolyPhen&#x02010;2 and SIFT analysis (Table&#x000a0;<xref rid="bjh13563-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="bjh13563-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Details of the <italic>CSNK1A1</italic> mutations identified in del(5q) <styled-content style="fixed-case">MDS</styled-content> patients and PolyPhen&#x02010;2 and <styled-content style="fixed-case">SIFT</styled-content> prediction of the effect of the mutations on protein function</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Patient ID</th><th align="left" valign="top" rowspan="1" colspan="1">Diagnosis</th><th align="left" valign="top" rowspan="1" colspan="1">Karyotype</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>CSNK1A1</italic> mutation</th><th align="left" valign="top" rowspan="1" colspan="1">PolyPhen&#x02010;2 prediction/score</th><th align="left" valign="top" rowspan="1" colspan="1">SIFT prediction/score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MDS05</td><td align="left" rowspan="1" colspan="1">RA</td><td align="left" rowspan="1" colspan="1">46,XX,t(1;3)(p33;p14),del(5)(q14q34)[21]/46,XX[4]</td><td align="left" rowspan="1" colspan="1">c.401A&#x0003e;T, p.H134L</td><td align="left" rowspan="1" colspan="1">Probably damaging/1</td><td align="left" rowspan="1" colspan="1">Damaging/0</td></tr><tr><td align="left" rowspan="1" colspan="1">MDS07</td><td align="left" rowspan="1" colspan="1">RA</td><td align="left" rowspan="1" colspan="1">46,XX,del(5)(q14q34),inv(9)(p11q13)c[30]</td><td align="left" rowspan="1" colspan="1">c.293A&#x0003e;G, p.E98G</td><td align="left" rowspan="1" colspan="1">Probably damaging/0&#x000b7;999</td><td align="left" rowspan="1" colspan="1">Damaging/0</td></tr><tr><td align="left" rowspan="1" colspan="1">MDS14</td><td align="left" rowspan="1" colspan="1">RA (5q&#x02010; syndrome)</td><td align="left" rowspan="1" colspan="1">46,XX,del(5)(q13q33)[26]/46,XX[4]</td><td align="left" rowspan="1" colspan="1">c.419A&#x0003e;C, p.D140A</td><td align="left" rowspan="1" colspan="1">Possibly damaging/0&#x000b7;877</td><td align="left" rowspan="1" colspan="1">Damaging/0</td></tr><tr><td align="left" rowspan="1" colspan="1">MDS36</td><td align="left" rowspan="1" colspan="1">RA (5q&#x02010; syndrome)</td><td align="left" rowspan="1" colspan="1">46,XX,del(5)(q?)[30]</td><td align="left" rowspan="1" colspan="1">c.292G&#x0003e;A, p.E98K</td><td align="left" rowspan="1" colspan="1">Probably damaging/0&#x000b7;999</td><td align="left" rowspan="1" colspan="1">Damaging/0</td></tr><tr><td align="left" rowspan="1" colspan="1">MDS72</td><td align="left" rowspan="1" colspan="1">RA</td><td align="left" rowspan="1" colspan="1">46,XX,del(5)(q?),del(7)(q?)[30]</td><td align="left" rowspan="1" colspan="1">c.292G&#x0003e;A, p.E98K</td><td align="left" rowspan="1" colspan="1">Probably damaging/0&#x000b7;999</td><td align="left" rowspan="1" colspan="1">Damaging/0</td></tr></tbody></table><table-wrap-foot><fn id="bjh13563-note-0002"><p>MDS, myelodysplastic syndrome; RA, refractory anaemia; SIFT, Sorting Intolerant from Tolerant.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="bjh13563-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(A) Representative examples of <italic>CSNK1A1</italic> mutations identified in exon 3 of the <italic>CSNK1A1</italic> gene in del(5q) myelodysplastic syndrome (<styled-content style="fixed-case">MDS</styled-content>) patients. The top panel shows part of the wild&#x02010;type sequence of exon 3 of <italic>CSNK1A1</italic>, with the nucleotides corresponding to Glutamic Acid (Glu) 98 highlighted in green above the relevant sequence peaks. The sequence of two del(5q) <styled-content style="fixed-case">MDS</styled-content> patients with <italic>CSNK1A1</italic> mutations in position 98 are shown with the mutation highlighted in&#x000a0;red. (B) Enrichment plot of the &#x02018;REACTOME_SIGNALING_BY_WNT&#x02019; gene set obtained using Gene Set Enrichment Analysis (<styled-content style="fixed-case">GSEA</styled-content>). (C) GSEA&#x02010;generated heatmap showing the expression levels (red=high, blue=low) of the genes in the &#x02018;REACTOME_SIGNALING_BY_WNT&#x02019; gene set in two del(5q) <styled-content style="fixed-case">MDS</styled-content> cases with <italic>CSNK1A1</italic> mutations and two del(5q) <styled-content style="fixed-case">MDS</styled-content> cases wild&#x02010;type for <italic>CSNK1A1</italic>.</p></caption><graphic id="nlm-graphic-1" xlink:href="BJH-171-210-g001"/></fig><p>The overall frequency of <italic>CSNK1A1</italic> mutations in our cohort was approximately 5% (5/104 of cases), which is consistent with the previous report suggesting that <italic>CSNK1A1</italic> mutations are rare events in del(5q) MDS (Schneider <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>). Patients with del(5q) show haploinsufficiency of <italic>CSNK1A1</italic> (because it maps to the CDR) and a small proportion of these patients also harbour mutation of the remaining allele<bold>.</bold> Next&#x02010;generation&#x02010;based targeted re&#x02010;sequencing data, using a panel targeting 25 genes mutated in various myeloid malignancies (Fernandez&#x02010;Mercado <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0006" ref-type="ref">2013</xref>), were available for four patients with and 37 patients without <italic>CSNK1A1</italic> mutations. The additional mutations found in the cases with <italic>CSNK1A1</italic> mutations were a <italic>RUNX1</italic> mutation in one patient and a <italic>U2AF1</italic> mutation in another patient and we did not therefore observe specific association of <italic>CSNK1A1</italic> mutations with other myeloid gene mutations. However, the number of cases analysed is clearly small, and the study of larger cohorts of del(5q) MDS cases with <italic>CSNK1A1</italic> mutations is required to determine whether robust associations with other gene mutations exist.</p><p>It has been recently reported that lenalidomide, a drug widely used to treat del(5q) MDS (List <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0011" ref-type="ref">2006</xref>), induces the ubiquitination and consequent degradation of <italic>CSNK1A1</italic> by the CRBN&#x02010;CRL4 E3 ubiquitin ligase, and that haploinsufficiency of CSNK1A1 might increase lenalidomide sensitivity in del(5q) haematopoietic cells (Fink <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0007" ref-type="ref">2014</xref>). Knockdown of CSNK1A1 sensitized primary CD34<sup>+</sup> cells to lenalidomide, suggesting that haploinsufficiency of CSNK1A1 might increase lenalidomide sensitivity in del(5q) haematopoietic cells (Fink <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0007" ref-type="ref">2014</xref>). One of our cases with the <italic>CSNK1A1</italic> mutation E98K [MDS72, carrying a del(5q) and a del(7q), Table&#x000a0;<xref rid="bjh13563-tbl-0001" ref-type="table-wrap">1</xref>] did not respond to treatment with lenalidomide.</p><p>
<italic>CSNK1A1</italic> encodes a protein that is a major regulator of the Wnt/&#x003b2;&#x02010;catenin pathway. We have re&#x02010;analysed our existing GEP data on MDS CD34<sup>+</sup> cells (Pellagatti <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0013" ref-type="ref">2010</xref>) to determine whether reduced expression of <italic>CSNK1A1</italic> in patients with del(5q) is associated with increased expression of the major downstream effectors of the Wnt/&#x003b2;&#x02010;catenin signalling pathway. The average expression fold change (patients <italic>versus</italic> median of 17 healthy controls) for <italic>CSNK1A1</italic> was 0&#x000b7;56 in 16 patients with 5q&#x02010; syndrome and 0&#x000b7;58 in 30 patients with del(5q) (Fig&#x000a0;S1), confirming that patients with 5q&#x02010; show haploinsufficient levels of this gene. The average expression fold change for <italic>CCND1</italic> (encoding cyclin D1)<italic>,</italic> a major downstream effector of Wnt/&#x003b2;&#x02010;catenin and regulator of cell cycle progression, was 1&#x000b7;42 in patients with 5q&#x02010; syndrome and 1&#x000b7;58 in patients with del(5q) (Fig&#x000a0;S1), showing that expression levels of this gene are increased by approximately 50% in patients with 5q&#x02010;. These data show that haploinsufficiency of <italic>CSNK1A1</italic> is associated with increased expression of Wnt/&#x003b2;&#x02010;catenin downstream effector genes in the HSC of MDS patients with del(5q) and are consistent with the previous demonstration that <italic>Csnk1a1<sup>+/&#x02212;</sup></italic> haematopoietic cells transplanted into wild&#x02010;type mice showed increased expression of cyclin D1 (accompanied by &#x003b2;&#x02010;catenin nuclear accumulation) (Schneider <italic>et&#x000a0;al</italic>, <xref rid="bjh13563-bib-0014" ref-type="ref">2014</xref>).</p><p>Gene expression profiling data were available for four patients with del(5q) for which we were able to determine the mutation status of <italic>CSNK1A1</italic>: two patients were mutated and two patients were wild&#x02010;type for <italic>CSNK1A1</italic>. We performed GSEA to compare the gene expression profiles of the two patients with <italic>CSNK1A1</italic> mutation with those of the two patients without mutations of this gene, in order to determine whether coordinated up&#x02010;regulation of pathways/processes associated with Wnt/&#x003b2;&#x02010;catenin function could be observed. The &#x02018;REACTOME_SIGNALING_BY_WNT&#x02019; gene set was found to be significantly up&#x02010;regulated (<italic>q</italic>&#x000a0;&#x0003c;&#x000a0;0&#x000b7;001) in the patients with <italic>CSNK1A1</italic> mutation compared with the patients without <italic>CSNK1A1</italic> mutations (Fig&#x000a0;<xref rid="bjh13563-fig-0001" ref-type="fig">1</xref>B, C). These data suggest that <italic>CSNK1A1</italic> mutations in del(5q) MDS may lead to an increase in the expression of genes involved in Wnt signalling.</p><p>In summary, we have confirmed the presence of <italic>CSNK1A1</italic> mutations in a small proportion of patients with del(5q) MDS and shown up&#x02010;regulation of &#x003b2;&#x02010;catenin target genes in the HSC of patients with del(5q) MDS. Our data support a central role for CSNK1A1 in the pathogenesis of MDS with del(5q).</p></sec><sec id="bjh13563-sec-0009"><title>Author contributions</title><p>AP and JB designed the research study; EB, AP and JS performed the research; CM, RK, SK, AG, SR, MJC, PF and JB contributed patient samples and helped with the analysis of the data; EB, AP, JS and JB analysed the data and wrote the paper.</p></sec><sec id="bjh13563-sec-0010"><title>Conflicts of interest</title><p>The authors have no competing interests.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;SI</bold>. Patient details.</p></caption><media xlink:href="BJH-171-210-s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Fig&#x000a0;S1.</bold> Expression ratios for <italic>CSNK1A1</italic> [<italic>n</italic>&#x000a0;=&#x000a0;3 cases with del(5q)] and <italic>CCND1</italic> [<italic>n</italic>&#x000a0;=&#x000a0;3 cases with del(5q)] obtained from real&#x02010;time quantitative PCR (blue bars) and Affymetrix experiments (red bars).</p></caption><media xlink:href="BJH-171-210-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="bjh13563-sec-0008"><title>Acknowledgements</title><p>This study was supported by Leukaemia &#x00026; Lymphoma Research (UK).</p></ack><ref-list content-type="cited-references" id="bjh13563-bibl-0001"><title>References</title><ref id="bjh13563-bib-0001"><mixed-citation publication-type="journal" id="bjh13563-cit-0001">
<string-name>
<surname>Boultwood</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fidler</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Strickson</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Watkins</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Gama</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kearney</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Tosi</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Kasprzyk</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>J.F.</given-names>
</string-name>, <string-name>
<surname>Jaju</surname>, <given-names>R.J.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wainscoat</surname>, <given-names>J.S.</given-names>
</string-name> (<year>2002</year>) <article-title>Narrowing and genomic annotation of the commonly deleted region of the 5q&#x02010; syndrome</article-title>. <source>Blood</source>, <volume>99</volume>, <fpage>4638</fpage>&#x02013;<lpage>4641</lpage>.<pub-id pub-id-type="pmid">12036901</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0002"><mixed-citation publication-type="journal" id="bjh13563-cit-0002">
<string-name>
<surname>Boultwood</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Pellagatti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cattan</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Lawrie</surname>, <given-names>C.H.</given-names>
</string-name>, <string-name>
<surname>Giagounidis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Malcovati</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Della Porta</surname>, <given-names>M.G.</given-names>
</string-name>, <string-name>
<surname>Jadersten</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Killick</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Fidler</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Cazzola</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Hellstrom&#x02010;Lindberg</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wainscoat</surname>, <given-names>J.S.</given-names>
</string-name> (<year>2007</year>) <article-title>Gene expression profiling of CD34+ cells in patients with the 5q&#x02010; syndrome</article-title>. <source>British Journal of Haematology</source>, <volume>139</volume>, <fpage>578</fpage>&#x02013;<lpage>589</lpage>.<pub-id pub-id-type="pmid">17916100</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0003"><mixed-citation publication-type="journal" id="bjh13563-cit-0003">
<string-name>
<surname>Boultwood</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Pellagatti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>McKenzie</surname>, <given-names>A.N.</given-names>
</string-name> &#x00026; <string-name>
<surname>Wainscoat</surname>, <given-names>J.S.</given-names>
</string-name> (<year>2010</year>) <article-title>Advances in the 5q&#x02010; syndrome</article-title>. <source>Blood</source>, <volume>116</volume>, <fpage>5803</fpage>&#x02013;<lpage>5811</lpage>.<pub-id pub-id-type="pmid">20733155</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0004"><mixed-citation publication-type="journal" id="bjh13563-cit-0004">
<string-name>
<surname>Dulak</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Stojanov</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Peng</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lawrence</surname>, <given-names>M.S.</given-names>
</string-name>, <string-name>
<surname>Fox</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Bandla</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Imamura</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Schumacher</surname>, <given-names>S.E.</given-names>
</string-name>, <string-name>
<surname>Shefler</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>McKenna</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Carter</surname>, <given-names>S.L.</given-names>
</string-name>, <string-name>
<surname>Cibulskis</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sivachenko</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Saksena</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Voet</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ramos</surname>, <given-names>A.H.</given-names>
</string-name>, <string-name>
<surname>Auclair</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sougnez</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Onofrio</surname>, <given-names>R.C.</given-names>
</string-name>, <string-name>
<surname>Guiducci</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Beroukhim</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Chang</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Landrenau</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Pennathur</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Ogino</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Luketich</surname>, <given-names>J.D.</given-names>
</string-name>, <string-name>
<surname>Golub</surname>, <given-names>T.R.</given-names>
</string-name>, <string-name>
<surname>Gabriel</surname>, <given-names>S.B.</given-names>
</string-name>, <string-name>
<surname>Lander</surname>, <given-names>E.S.</given-names>
</string-name>, <string-name>
<surname>Beer</surname>, <given-names>D.G.</given-names>
</string-name>, <string-name>
<surname>Godfrey</surname>, <given-names>T.E.</given-names>
</string-name>, <string-name>
<surname>Getz</surname>, <given-names>G.</given-names>
</string-name> &#x00026; <string-name>
<surname>Bass</surname>, <given-names>A.J.</given-names>
</string-name> (<year>2013</year>) <article-title>Exome and whole&#x02010;genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity</article-title>. <source>Nature Genetics</source>, <volume>45</volume>, <fpage>478</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">23525077</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0005"><mixed-citation publication-type="journal" id="bjh13563-cit-0005">
<string-name>
<surname>Elyada</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Pribluda</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>, <given-names>R.E.</given-names>
</string-name>, <string-name>
<surname>Morgenstern</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Brachya</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Cojocaru</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Snir&#x02010;Alkalay</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Burstain</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Haffner&#x02010;Krausz</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Jung</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Wiener</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Alitalo</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Oren</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Pikarsky</surname>, <given-names>E.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ben&#x02010;Neriah</surname>, <given-names>Y.</given-names>
</string-name> (<year>2011</year>) <article-title>CKI&#x003b1; ablation highlights a critical role for p53 in invasiveness control</article-title>. <source>Nature</source>, <volume>470</volume>, <fpage>409</fpage>&#x02013;<lpage>413</lpage>.<pub-id pub-id-type="pmid">21331045</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0006"><mixed-citation publication-type="journal" id="bjh13563-cit-0006">
<string-name>
<surname>Fernandez&#x02010;Mercado</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Burns</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Pellagatti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Giagounidis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Germing</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Agirre</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Prosper</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Aul</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Killick</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Wainscoat</surname>, <given-names>J.S.</given-names>
</string-name>, <string-name>
<surname>Schuh</surname>, <given-names>A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Boultwood</surname>, <given-names>J.</given-names>
</string-name> (<year>2013</year>) <article-title>Targeted re&#x02010;sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes</article-title>. <source>Haematologica</source>, <volume>98</volume>, <fpage>1856</fpage>&#x02013;<lpage>1864</lpage>.<pub-id pub-id-type="pmid">23831921</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0007"><mixed-citation publication-type="journal" id="bjh13563-cit-0007">
<string-name>
<surname>Fink</surname>, <given-names>E.C.</given-names>
</string-name>, <string-name>
<surname>Kr&#x000f6;nke</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Hurst</surname>, <given-names>S.N.</given-names>
</string-name>, <string-name>
<surname>Udeshi</surname>, <given-names>N.D.</given-names>
</string-name>, <string-name>
<surname>Svinkina</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>McConkey</surname>, <given-names>M.E.</given-names>
</string-name>, <string-name>
<surname>J&#x000e4;r&#x000e5;s</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Bullinger</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Carr</surname>, <given-names>S.A.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ebert</surname>, <given-names>B.L.</given-names>
</string-name> (<year>2014</year>) <article-title>Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with Del(5q)</article-title>. <source>Blood</source>, <volume>124</volume>, <fpage>4</fpage>.<pub-id pub-id-type="pmid">24993875</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0008"><mixed-citation publication-type="journal" id="bjh13563-cit-0008">
<string-name>
<surname>Giagounidis</surname>, <given-names>A.A.</given-names>
</string-name>, <string-name>
<surname>Germing</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Haase</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hildebrandt</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Schlegelberger</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Schoch</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Wilkens</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Heinsch</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Willems</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Aivado</surname>, <given-names>M.</given-names>
</string-name> &#x00026; <string-name>
<surname>Aul</surname>, <given-names>C.</given-names>
</string-name> (<year>2004</year>) <article-title>Clinical, morphological, cytogenetic, and prognostic features of patients&#x000a0;with myelodysplastic syndromes and del(5q) including band q31</article-title>. <source>Leukemia</source>, <volume>18</volume>, <fpage>113</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">14586479</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0009"><mixed-citation publication-type="journal" id="bjh13563-cit-0009">
<string-name>
<surname>Graubert</surname>, <given-names>T.A.</given-names>
</string-name>, <string-name>
<surname>Shen</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Okeyo&#x02010;Owuor</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Lunn</surname>, <given-names>C.L.</given-names>
</string-name>, <string-name>
<surname>Shao</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Krysiak</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Harris</surname>, <given-names>C.C.</given-names>
</string-name>, <string-name>
<surname>Koboldt</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Larson</surname>, <given-names>D.E.</given-names>
</string-name>, <string-name>
<surname>McLellan</surname>, <given-names>M.D.</given-names>
</string-name>, <string-name>
<surname>Dooling</surname>, <given-names>D.J.</given-names>
</string-name>, <string-name>
<surname>Abbott</surname>, <given-names>R.M.</given-names>
</string-name>, <string-name>
<surname>Fulton</surname>, <given-names>R.S.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Kalicki&#x02010;Veizer</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>O'Laughlin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Grillot</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Baty</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Heath</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Frater</surname>, <given-names>J.L.</given-names>
</string-name>, <string-name>
<surname>Nasim</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Link</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Tomasson</surname>, <given-names>M.H.</given-names>
</string-name>, <string-name>
<surname>Westervelt</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>DiPersio</surname>, <given-names>J.F.</given-names>
</string-name>, <string-name>
<surname>Mardis</surname>, <given-names>E.R.</given-names>
</string-name>, <string-name>
<surname>Ley</surname>, <given-names>T.J.</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>, <given-names>R.K.</given-names>
</string-name> &#x00026; <string-name>
<surname>Walter</surname>, <given-names>M.J.</given-names>
</string-name> (<year>2012</year>) <article-title>Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes</article-title>. <source>Nature Genetics</source>, <volume>44</volume>, <fpage>53</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">22158538</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0010"><mixed-citation publication-type="journal" id="bjh13563-cit-0010">
<string-name>
<surname>Heaney</surname>, <given-names>M.L.</given-names>
</string-name> &#x00026; <string-name>
<surname>Golde</surname>, <given-names>D.W.</given-names>
</string-name> (<year>1999</year>) <article-title>Myelodysplasia</article-title>. <source>New England Journal of Medicine</source>, <volume>340</volume>, <fpage>1649</fpage>&#x02013;<lpage>1660</lpage>.<pub-id pub-id-type="pmid">10341278</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0011"><mixed-citation publication-type="journal" id="bjh13563-cit-0011">
<string-name>
<surname>List</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Dewald</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Giagounidis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Raza</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Feldman</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Powell</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Greenberg</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Stone</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Reeder</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Wride</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Patin</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zeldis</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Knight</surname>, <given-names>R.</given-names>
</string-name> &#x00026; <collab collab-type="authors">Myelodysplastic Syndrome&#x02010;003 Study, I</collab>
. (<year>2006</year>) <article-title>Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion</article-title>. <source>New England Journal of Medicine</source>, <volume>355</volume>, <fpage>1456</fpage>&#x02013;<lpage>1465</lpage>.<pub-id pub-id-type="pmid">17021321</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0012"><mixed-citation publication-type="journal" id="bjh13563-cit-0012">
<string-name>
<surname>Papaemmanuil</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Cazzola</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Boultwood</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Malcovati</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Vyas</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Bowen</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pellagatti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wainscoat</surname>, <given-names>J.S.</given-names>
</string-name>, <string-name>
<surname>Hellstrom&#x02010;Lindberg</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Gambacorti&#x02010;Passerini</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Godfrey</surname>, <given-names>A.L.</given-names>
</string-name>, <string-name>
<surname>Rapado</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Cvejic</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Rance</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>McGee</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Ellis</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Mudie</surname>, <given-names>L.J.</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>, <given-names>P.J.</given-names>
</string-name>, <string-name>
<surname>McLaren</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Massie</surname>, <given-names>C.E.</given-names>
</string-name>, <string-name>
<surname>Tarpey</surname>, <given-names>P.S.</given-names>
</string-name>, <string-name>
<surname>Varela</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Nik&#x02010;Zainal</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Davies</surname>, <given-names>H.R.</given-names>
</string-name>, <string-name>
<surname>Shlien</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Jones</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Raine</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Hinton</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Butler</surname>, <given-names>A.P.</given-names>
</string-name>, <string-name>
<surname>Teague</surname>, <given-names>J.W.</given-names>
</string-name>, <string-name>
<surname>Baxter</surname>, <given-names>E.J.</given-names>
</string-name>, <string-name>
<surname>Score</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Galli</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Della Porta</surname>, <given-names>M.G.</given-names>
</string-name>, <string-name>
<surname>Travaglino</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Groves</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tauro</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Munshi</surname>, <given-names>N.C.</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>, <given-names>K.C.</given-names>
</string-name>, <string-name>
<surname>El&#x02010;Naggar</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Fischer</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Mustonen</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Warren</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Cross</surname>, <given-names>N.C.</given-names>
</string-name>, <string-name>
<surname>Green</surname>, <given-names>A.R.</given-names>
</string-name>, <string-name>
<surname>Futreal</surname>, <given-names>P.A.</given-names>
</string-name>, <string-name>
<surname>Stratton</surname>, <given-names>M.R.</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>, <given-names>P.J.</given-names>
</string-name> &#x00026; <collab collab-type="authors">Chronic Myeloid Disorders Working Group of the International Cancer Genome, C</collab>
. (<year>2011</year>) <article-title>Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts</article-title>. <source>New England Journal of Medicine</source>, <volume>365</volume>, <fpage>1384</fpage>&#x02013;<lpage>1395</lpage>.<pub-id pub-id-type="pmid">21995386</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0013"><mixed-citation publication-type="journal" id="bjh13563-cit-0013">
<string-name>
<surname>Pellagatti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Cazzola</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Giagounidis</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Perry</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Malcovati</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Della Porta</surname>, <given-names>M.G.</given-names>
</string-name>, <string-name>
<surname>Jadersten</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Killick</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Verma</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Norbury</surname>, <given-names>C.J.</given-names>
</string-name>, <string-name>
<surname>Hellstrom&#x02010;Lindberg</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Wainscoat</surname>, <given-names>J.S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Boultwood</surname>, <given-names>J.</given-names>
</string-name> (<year>2010</year>) <article-title>Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells</article-title>. <source>Leukemia</source>, <volume>24</volume>, <fpage>756</fpage>&#x02013;<lpage>764</lpage>.<pub-id pub-id-type="pmid">20220779</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0014"><mixed-citation publication-type="journal" id="bjh13563-cit-0014">
<string-name>
<surname>Schneider</surname>, <given-names>R.K.</given-names>
</string-name>, <string-name>
<surname>Adema</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Heckl</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Jaras</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mallo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lord</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name>
<surname>Chu</surname>, <given-names>L.P.</given-names>
</string-name>, <string-name>
<surname>McConkey</surname>, <given-names>M.E.</given-names>
</string-name>, <string-name>
<surname>Kramann</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Mullally</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bejar</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Sole</surname>, <given-names>F.</given-names>
</string-name> &#x00026; <string-name>
<surname>Ebert</surname>, <given-names>B.L.</given-names>
</string-name> (<year>2014</year>) <article-title>Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS</article-title>. <source>Cancer Cell</source>, <volume>26</volume>, <fpage>509</fpage>&#x02013;<lpage>520</lpage>.<pub-id pub-id-type="pmid">25242043</pub-id></mixed-citation></ref><ref id="bjh13563-bib-0015"><mixed-citation publication-type="journal" id="bjh13563-cit-0015">
<string-name>
<surname>Woll</surname>, <given-names>P.S.</given-names>
</string-name>, <string-name>
<surname>Kjallquist</surname>, <given-names>U.</given-names>
</string-name>, <string-name>
<surname>Chowdhury</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Doolittle</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Wedge</surname>, <given-names>D.C.</given-names>
</string-name>, <string-name>
<surname>Thongjuea</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Erlandsson</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ngara</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Deng</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Mead</surname>, <given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Stenson</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Giustacchini</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Duarte</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Giannoulatou</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Karimi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Scharenberg</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Mortera&#x02010;Blanco</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Macaulay</surname>, <given-names>I.C.</given-names>
</string-name>, <string-name>
<surname>Clark</surname>, <given-names>S.A.</given-names>
</string-name>, <string-name>
<surname>Dybedal</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Josefsen</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Fenaux</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hokland</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Holm</surname>, <given-names>M.S.</given-names>
</string-name>, <string-name>
<surname>Cazzola</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Malcovati</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Tauro</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bowen</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Boultwood</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Pellagatti</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Pimanda</surname>, <given-names>J.E.</given-names>
</string-name>, <string-name>
<surname>Unnikrishnan</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Vyas</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Gohring</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Schlegelberger</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Tobiasson</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kvalheim</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Constantinescu</surname>, <given-names>S.N.</given-names>
</string-name>, <string-name>
<surname>Nerlov</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Nilsson</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>, <given-names>P.J.</given-names>
</string-name>, <string-name>
<surname>Sandberg</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Papaemmanuil</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Hellstrom&#x02010;Lindberg</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Linnarsson</surname>, <given-names>S.</given-names>
</string-name> &#x00026; <string-name>
<surname>Jacobsen</surname>, <given-names>S.E.</given-names>
</string-name> (<year>2014</year>) <article-title>Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in&#x000a0;vivo</article-title>. <source>Cancer Cell</source>, <volume>25</volume>, <fpage>794</fpage>&#x02013;<lpage>808</lpage>.<pub-id pub-id-type="pmid">24835589</pub-id></mixed-citation></ref></ref-list></back></article>